Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Carlumab (Anti-CCL2 / MCP1)
For research use only. Not for use in humans.

Carlumab (Anti-CCL2 / MCP1)

Synonyms: Ccl2,MCP-1

Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD.

Carlumab (Anti-CCL2 / MCP1)

Click to purchase the isotype control of Carlumab (Anti-CCL2 / MCP1)

Quality Control

Batch: A257301 Purity: 99% Protein concentration: 3.8mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD.

Product Details

CAS No. 915404-94-3
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07651397 NOT_YET_RECRUITING Autosomal Dominant Polycystic Kidney Disease (ADPKD) Assaf-Harofeh Medical Center 2026-07-10
NCT02261545 UNKNOWN Diabetes Mellitus Type II Tehran University of Medical Sciences 2014-09 PHASE4
NCT01340222 COMPLETED Preterm Labour Centre Hospitalier Universitaire Dijon 2011-03
NCT00992186 COMPLETED Drug: Carlumab Prostate Cancer Centocor Research & Development, Inc. 2009-09 PHASE2
NCT00385931 COMPLETED Drug: Valsartan and simvastatin Hypertension; Hypercholesterolemia; Dyslipidemia Novartis 2002-01 PHASE3
NCT01204996 COMPLETED Drug: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injec Cancer Centocor, Inc. 2010-05 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.